In the era of precision medicine, the precise treatment of malignant tumors has attracted much attention, and various molecular and phenotypic studies will bring more accurate diagnosis, more reasonable treatment, and more effective prevention to different subgroups of patients. It has been reported that immune-related mechanisms are involved in the development and progression of tumors, and immunotherapy has emerged as a promising treatment option for patients with different cancers. Targeting immune checkpoints such as PD-1 and PD-L1 can effectively improve the prognosis of patients. However, only a small percentage of patients could benefit from it due to the irregularity in clinical response. Combination therapies, immunotherapy with chemotherapy, radiation therapy, and targeted therapy, have been applied to various tumors, but there is still an urgent need to uncover the mechanisms underpinning cancer immune regulation and immunotherapy, and to identify novel biomarkers as predictors of cancer immunotherapy response, leading to novel therapeutic approaches to alter the courses and improve the efficacy of immunotherapy.
The goal of this Research Topic is to provide new advances and insights into promising biomarkers for predicting response to cancer immunotherapy and elucidate the potential molecular mechanisms. These biomarkers can be used to select patients sensitive to targeted therapy or immunotherapy, and their diagnostic, therapeutic, and prognostic effects could enhance the impact on cancer patients. We welcome submissions covering, but are not limited to, the following aspects:
1. Biomarkers and therapeutic targets for predicting response to cancer immunotherapy
2. Identification of epigenetic biomarkers in cancer immunotherapy
3. Potential of ncRNAs in cancer prognosis and/or immunotherapy
4. Multi-omics analysis to explore biomarkers for cancer immunotherapy
5. Molecular mechanisms related to immune regulation and immunotherapy in different types of cancer
6. Studies on related subtypes of tumor patients sensitive to immunotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
In the era of precision medicine, the precise treatment of malignant tumors has attracted much attention, and various molecular and phenotypic studies will bring more accurate diagnosis, more reasonable treatment, and more effective prevention to different subgroups of patients. It has been reported that immune-related mechanisms are involved in the development and progression of tumors, and immunotherapy has emerged as a promising treatment option for patients with different cancers. Targeting immune checkpoints such as PD-1 and PD-L1 can effectively improve the prognosis of patients. However, only a small percentage of patients could benefit from it due to the irregularity in clinical response. Combination therapies, immunotherapy with chemotherapy, radiation therapy, and targeted therapy, have been applied to various tumors, but there is still an urgent need to uncover the mechanisms underpinning cancer immune regulation and immunotherapy, and to identify novel biomarkers as predictors of cancer immunotherapy response, leading to novel therapeutic approaches to alter the courses and improve the efficacy of immunotherapy.
The goal of this Research Topic is to provide new advances and insights into promising biomarkers for predicting response to cancer immunotherapy and elucidate the potential molecular mechanisms. These biomarkers can be used to select patients sensitive to targeted therapy or immunotherapy, and their diagnostic, therapeutic, and prognostic effects could enhance the impact on cancer patients. We welcome submissions covering, but are not limited to, the following aspects:
1. Biomarkers and therapeutic targets for predicting response to cancer immunotherapy
2. Identification of epigenetic biomarkers in cancer immunotherapy
3. Potential of ncRNAs in cancer prognosis and/or immunotherapy
4. Multi-omics analysis to explore biomarkers for cancer immunotherapy
5. Molecular mechanisms related to immune regulation and immunotherapy in different types of cancer
6. Studies on related subtypes of tumor patients sensitive to immunotherapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
